Drugs / Trelegy Ellipta
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Trelegy Ellipta | — | 2017-11-15 | europa.eu ↗ |
| Approved | US (FDA) | TRELEGY ELLIPTA | — | 2017-09-18 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06282861 | Feb 2024 → Jan 2025 | chronic obstructive pulmonary disease | Fundacio Privada Mon Clinic Barcelona | Terminated | No outcome recorded |
| Phase 4 | NCT04606394 | Dec 2020 → Dec 2021 | chronic obstructive pulmonary disease | Pulmonary Research Institute of Southeast Michigan | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trelegy Ellipta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06282861 ↗ |
| Route | Inhaled | “Trelegy Ellipta 100/62.5/25Mcg Inh 30D” NCT04606394 ↗ |